Pulmonx Corp
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
LUNG$2.800.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $76,549 | $70,905 |
| Restricted cash | 261 | 257 |
| Short-term marketable securities | — | 30,577 |
| Accounts receivable, net | 13,797 | 13,120 |
| Inventory | 16,248 | 16,915 |
| Prepaid expenses and other current assets | 4,380 | 4,474 |
| Total current assets | 111,235 | 136,248 |
| Long-term inventory | 2,474 | 1,681 |
| Property and equipment, net | 2,443 | 2,907 |
| Goodwill | 2,333 | 2,333 |
| Right of use assets | 18,279 | 18,545 |
| Other long-term assets | 1,517 | 1,136 |
| Total assets | $138,281 | $162,850 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $6,420 | $3,827 |
| Accrued liabilities | 14,936 | 16,472 |
| Income taxes payable | 189 | 49 |
| Deferred revenue | 92 | 135 |
| Short-term debt | 105 | 3,176 |
| Current lease liabilities | 1,136 | 778 |
| Total current liabilities | 22,878 | 24,437 |
| Deferred tax liability | 47 | 87 |
| Long-term lease liabilities | 18,298 | 18,515 |
| Long-term debt | 37,025 | 34,002 |
| Total liabilities | 78,248 | 77,041 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of September 30, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value, 200,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 41,246,534 shares issued and outstanding as of September 30, 2025 and 39,785,969 shares issued and outstanding as of December 31, 2024 | 41 | 40 |
|---|---|---|
| Additional paid-in capital | 568,887 | 551,211 |
| Accumulated other comprehensive income | 2,238 | 2,113 |
| Accumulated deficit | (511,133) | (467,555) |
| Total stockholders’ equity | 60,033 | 85,809 |
| Total liabilities and stockholders’ equity | $138,281 | $162,850 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.